The reported quarter was far above the earnings bar, but the comparison is unusually distorted. Published estimates called for roughly a $0.31 per-share loss and about $25 million of revenue; MeiraGTx instead reported $1.71 diluted EPS and $321.4 million of revenue.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Total revenue | $321.4M (Income Statement) | $3.7M prior year; ~$25M published consensus |
| Diluted EPS | $1.71 (Income Statement) | $(0.48) prior year; ~$(0.31) consensus |
| Net income attributable to shareholders | $160.7M (Income Statement) | $(38.8)M prior year |
| Research and development expense | $57.8M (Income Statement) | $33.5M prior year |
| Cash and cash equivalents | $143.2M (Balance Sheet) | $65.9M at December 31, 2025 |
| Basic shares outstanding | 91.4M (Income Statement) | 80.6M prior year |
The EPS beat came mainly from transaction-related revenue, not a recurring commercial inflection. Of the $321.4 million quarterly revenue, $204.6 million was license revenue tied to licenses granted to Reogen, while another $104.9 million was related-party service revenue that included deferred-revenue release and transition services. Those items produced $244.4 million of operating income, but they do not establish a repeatable quarterly earnings base. (Financial Results; Income Statement)
Underlying investment intensity increased rather than disappeared. Research and development spending rose 73% year over year to $57.8 million, driven by the bota-vec reacquisition, AAV2-hAQP1 manufacturing and clinical work. The quarter also included a $71.9 million loss from the equity-method investee and a $5.2 million derivative-liability loss, underscoring that the accounting profit was heavily shaped by strategic transactions. (Financial Results; Income Statement)
The more durable improvement is financial runway, not profitability. Cash and cash equivalents reached $143.2 million, while the company says post-quarter financing and expected payments should fund operations into the second half of 2028. That support came with additional obligations: $100 million of note payable remained on the balance sheet, shares outstanding increased to 94.2 million at June 30, and future product sales may carry royalty payments to Oberland and J&J. (Financial Results; Balance Sheet; Second Quarter 2026 Highlights)
The clinical and regulatory timeline is largely confirmation rather than a fresh surprise. Bota-vec filings are still expected in 2026, while the pivotal AAV2-hAQP1 readout remains targeted for the second quarter of 2027. The acquisition, financing, Breakthrough Therapy designation and positive three-year data were already disclosed before this filing, so the new information is primarily the magnitude and composition of the quarter's accounting revenue—not a new clinical result. (Second Quarter 2026 Highlights)
Net read: a clean headline beat, but only a modest fundamental upgrade. Versus the published earnings expectation, this is a clear Beat; versus the business investors ultimately need to value, it is narrower because the earnings surge is nonrecurring, share count and royalty obligations increased, and the next major value test remains clinical and regulatory execution. (Income Statement; Balance Sheet; Second Quarter 2026 Highlights)
Read the original 8-K on SEC EDGAR ↗